Merck Serono, Domain Join For Parkinson's | January 24, 2011 Issue - Vol. 89 Issue 4 | Chemical & Engineering News
Volume 89 Issue 4 | p. 19 | Concentrates
Issue Date: January 24, 2011

Merck Serono, Domain Join For Parkinson's

Department: Business
Keywords: Parkinson's disease, GPCR

Merck Serono and Domain Therapeutics will jointly develop allosteric modulators of mGluR4, a glutamate receptor that is implicated in Parkinson’s and other neurodegenerative diseases. Domain initially scores $2.7 million in research funding and an up-front fee, and it could bring in up to $175 million in milestones as the first two products move through clinical trials. Domain will hand over optimized compounds discovered in its internally developed chemical series.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment